Are thermogenic proteins and adipokine chemerin affected by monoclonal antibody therapy in asthma?
EURASIAN JOURNAL OF PULMONOLOGY, vol.21, no.3, pp.161-166, 2019 (ESCI, TRDizin)
- Publication Type: Article / Article
- Volume: 21 Issue: 3
- Publication Date: 2019
- Doi Number: 10.4103/ejop.ejop_60_18
- Journal Name: EURASIAN JOURNAL OF PULMONOLOGY
- Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Page Numbers: pp.161-166
- Keywords: Asthma, CD16-56, CD80, chemerin, interleukin-1 beta, irisin, natural killer activity, omalizumab, ALLERGIC-ASTHMA, DISEASE, OMALIZUMAB, WEAKNESS, IRISIN, COPD
- Akdeniz University Affiliated: Yes
Abstract
BACKGROUND: Irisin is a thermogenic protein that sources outgoing energy by converting white adipose tissue to brown adipose tissue. Chemerin is originally identified as a chemoattractant protein that mainly mediating the chemotaxis of dendritic cells and natural killer cells (NKCs). The aim of this study is to assess the potential impact of immune modulation-related chemerin and irisin concentrations together with cell surface markers (CSM) in allergic asthmatic patients under omalizumab treatment.